Breakthrough lung cancer drug gets MHRA green light

News

Breakthrough lung cancer drug gets MHRA green light

In News

A cutting-edge treatment for lung cancer patients has provisionally been given the green light in the UK, meaning NHS patients will be the first in Europe to be offered it.

Sotorasib, which is taken as a tablet and is marketed as Lumykras, was granted a conditional marketing authorisation by the MHRA on Friday. It targets KRAS G12C, a mutation found in a quarter of all tumours, and has been shown to permanently lock it in an inactive state and prevent cell growth, says manufacturer Amgen UK.  

The NHS will begin offering the drug to eligible lung cancer patients within weeks through an early access agreement with Amgen, while NICE completes its appraisal process.

The announcement follows a 40-year search for a treatment for KRAS G12C. It has been approved as part of Project Orbis, an international programme between the US FDA and other regulatory agencies aimed at speeding up the review of new oncology medicines.

Described as the first drugof its kind, it is hoped that sotorasib could offer a breakthrough in the treatment of other deadly cancers including pancreatic and colorectal cancers.

Dr. Tony Patrikios, executive medical director at Amgen UK and Ireland, said: “Today’s conditional marketing authorisation by the MHRA marks an important moment in treating lung cancer patients, with a new targeted therapy, who have failed first-line treatment and face extremely poor outcomes with limited further treatment options.

“This reflects the clinical investigation programme, demonstrating the use of sotorasib in adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have progressed on, or are intolerant to, platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotherapy.”

“Sotorasib is the first targeted KRAS G12C inhibitor to be authorised for use in Great Britain. Targeting KRAS has been a 40-year quest by scientists and researchers around the World. Approximately 13 per cent of patients with NSCLC harbour the KRAS G12C mutation and whilst approximately 48,000 people are diagnosed with lung cancer every year in the UK  it is estimated that 5,000 of these people will have KRAS G12C-mutated NSCLC.”

Professor Charles Swanton, Cancer Research UK’s chief clinician, said: “Sotorasib is one of the most exciting breakthroughs in lung cancer treatment in 20 years, targeting a cancer gene that was previously untargetable and built on decades of laboratory research that’s unravelled cancer’s inner workings.

“This medicine expands our list of effective precision therapies in lung cancer that are helping to improve survival for patients with limited options. It’s great news that patients in England will now benefit from this novel treatment.”

Record my learning outcomes

News

Inspiring stories related to health, fitness and the pursuit of wellbeing

Share:

More like this

bookmark_icon_off
News

Charity attacks plans to raise free prescription age to 66

The Government plans to increase the age for prescription exemptions to 66 years.

1 Min Article

bookmark_icon_off
News

Advanz lands multi-million fine for inflating liothyronine prices

'Price optimisation' strategy saw prices hiked by 6,000 per cent over eight years.

2 Min Article

bookmark_icon_off
News

95pc of contractors will receive full Covid claim from Government

The vast majority of contractors will receive their full claim from the BSA in October.

1 Min Article

bookmark_icon_off
News

Boots partners with Deliveroo on home orders

Home deliveries launch from 14 Boots stores for customers using Deliveroo.

1 Min Article

bookmark_icon_off
News

Welsh government presses ahead with ePrescribing

The plans will improve the way patients and healthcare professionals access and manage medicines.

1 Min Article

bookmark_icon_off
News

Independent Pharmacy Awards announces finalists

ICP has announced the finalists for the Independent Pharmacy Awards at the House of Commons.

1 Min Article

Recommended Learning

bookmark_icon_off
Sponsored education

Helping customers treat & care for their scalp

Understanding the causes and symptoms of some common scalp conditions will help you to make a real difference to your customers’ lives. Complete this module to discover self-care and product advice to help ease symptoms and maintain scalp health.

10 Min Module

bookmark_icon_off
Sponsored education

Sore throats and antibiotic resistance

This module will help you to understand and educate customers about the risks of antibiotic resistance, and recommend products to help them effectively manage their sore throat symptoms.

 

10 Min Module

Sponsored education

Treating fungal nail infections

Understand how fungal nail infections develop and help manage customer expectations around treatment

10 Min Module

bookmark_icon_off
Sponsored education

Challenge your thinking on warts and verrucas

Discover different treatment options for warts and verruas and when to recommend them to your customers, based on their individual needs

17 Min Module

bookmark_icon_off
Sponsored education

Confident pet health conversations

Learn 3 key steps to having more confident conversations with customers about pet health products.

3 Min Module

bookmark_icon_off
Sponsored education

Biological medicines and biosimilars

This module explores biological and biosimilar medicines, and will increase your understanding of the guidelines surrounding the brand prescribing of these drugs and your role in their supply

10 Min Module